{"brief_title": "Phase I/II Study of Monoclonal Factor IX Concentrate for Factor IX Deficiency", "brief_summary": "OBJECTIVES: Assess the safety and long-term efficacy of monoclonal factor IX concentrate in patients with factor IX deficiency.", "detailed_description": "PROTOCOL OUTLINE: Patients receive monoclonal factor IX replacement therapy as inpatients. Patients with a satisfactory response receive further therapy as needed for bleeding for up to 36 months at home.", "condition": "Factor IX Deficiency", "intervention_type": "Drug", "intervention_name": "monoclonal factor IX replacement therapy", "criteria": "PROTOCOL ENTRY CRITERIA: Patients with factor IX deficiency.", "gender": "All", "minimum_age": "12 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00004801.xml"}